ArticleInfection and drug resistance2022
Risk Factors for a Hospital-Acquired Carbapenem-Resistant
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Risk factors for carbapenem-resistant Klebsiella pneumoniae infection in hospitalized patients: a meta-analysis.Frontiers in cellular and infection microbiology · 2026Pooled it
- Clinical outcomes and mortality in carbapenem-resistant versus susceptible Klebsiella pneumoniae bloodstream infections in intensive care units.BMC infectious diseases · 2026Article
- Molecular characteristics, clinical risk factors, and outcomes of Klebsiella pneumoniae bloodstream infections in infants.BMC microbiology · 2026Article
- Risk factors for bloodstream infections and mortality in carbapenem-resistant versus susceptible Klebsiella pneumoniae: a six-year retrospective cohort study.BMC infectious diseases · 2026Article
- Gram-negative gut colonization in children newly diagnosed with malignancy: microbiology, antimicrobial resistance pattern, and clinical implications.Gut pathogens · 2026Article
- Predictive model for carbapenem-resistant Klebsiella pneumoniae bloodstream infection based on a nomogram: a retrospective study.BMC research notes · 2025Article
- Research and predictive analysis of the disease burden of bloodstream infectious diseases in China.BMC infectious diseases · 2025Article
- Unveiling the potential of spirulina algal extract as promising antibacterial and antibiofilm agent against carbapenem-resistant Klebsiella pneumoniae: in vitro and in vivo study.Microbial cell factories · 2025Article
- Seven-year change of prevalence, clinical risk factors, and mortality of patients with carbapenem-resistantFrontiers in microbiology · 2025Article
- Article
- Clinical and Genomic Characteristics of Carbapenem-ResistantInfection and drug resistance · 2025Article
- Epidemiology, antimicrobial resistance profile, associated risk factors and management of carbapenem resistant Klebsiella pneumoniae in children under 5 with suspected sepsis in Ethiopia.BMC infectious diseases · 2024Article
- Chromosomal integration and plasmid fusion occurring in ST20 carbapenem-resistantEmerging microbes & infections · 2024Article
- Solithromycin in Combination with Other Antimicrobial Agents Against the Carbapenem ResistantIndian journal of microbiology · 2024Article
- Factors Associated with Extended-Spectrum β-Lactamases and Carbapenem-ResistantPathogens (Basel, Switzerland) · 2023Article
- Clinical Outcomes and Risk Factors for Death following Carbapenem-Resistant Klebsiella pneumoniae Infection in Solid Organ Transplant Recipients.Microbiology spectrum · 2023Article
- Risk Factors and Mortality of Elderly Patients with Hospital-Acquired Pneumonia of Carbapenem-ResistantInfection and drug resistance · 2023Article
- Comparison of bloodstream and non-bloodstream infections caused by carbapenem-resistantFrontiers in medicine · 2023Article
- Epidemiology, Drug Resistance, and Risk Factors for Mortality Among Hematopoietic Stem Cell Transplantation Recipients with Hospital-AcquiredInfection and drug resistance · 2022Article
- Molecular Epidemiology, Clinical Characteristics and Risk Factors for Bloodstream Infection of Multidrug-ResistantInfection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to describe trends in PATIENTS AND
methodsWe recorded the results of antimicrobial susceptibility testing of 396 KP-positive blood cultures from January 2016 to December 2020. A total of 277 patients with a KP BSI were included in this study, of which 171 had a hospital-acquired infection and 84 had a hospital-acquired CRKP BSI. Multivariate logistic regression analysis was used to identify risk factors for a hospital-acquired CRKP BSI and 28-day mortality from a hospital-acquired KP BSI.
resultsThe proportion of hospital-acquired infections among KP BSI patients increased from 53.1% in 2016 to 72.8% in 2020. The detection rate of CRKP among KP BSI patients increased from 18.8% in 2016 to 37.7% in 2020. Multivariate logistic regression showed that β-lactam/β-lactamase inhibitor combinations (BLBLIs) exposure (
conclusionThe incidence of hospital-acquired KP BSI continues to rise and the proportion of CRKP BSI is also increasing. We believe that the use of the BLBLIs needs to be carefully evaluated in hospital-acquired infection. Hospital-acquired KP BSI Patients with CRKP BSI, septic shock, mechanical ventilation and deficiency of platelets are more likely to have a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.